Raffi, François <br/><br/>
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.  [electronic resource] 

 -  Lancet (London, England)  Nov 2014 
 - 1942-51 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(14)61170-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Anti-HIV Agents--therapeutic use<br/>CD4 Lymphocyte Count<br/>Cholesterol, HDL--metabolism<br/>Cholesterol, LDL--metabolism<br/>Darunavir<br/>Deoxycytidine--analogs & derivatives<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Emtricitabine<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Organophosphonates--therapeutic use<br/>Pyrrolidinones--therapeutic use<br/>Raltegravir Potassium<br/>Ritonavir--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Tenofovir<br/>Treatment Outcome